Bimekizumab is a Dual Anti-human IL17A/IL-17F Inhibitor for Plaque Psoriasis Research
Psoriatic arthritis (PsA) is a complex and heterogeneous inflammatory disease that affects 20% to 30% of patients. Pro-inflammatory cytokines are the potential targets in inflammatory diseases. They have led to…